Engineered Antibody Binding Collagen I Telopeptide
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies are ineffective in preventing or reducing excessive collagen fibril deposition associated with fibrotic disorders, which leads to scarring and functional impairments in various tissues and organs.
Innovation Solution
Development of chimeric, humanized, or single-chain antibodies that specifically bind to the C-terminal telopeptide of the α2(I) chain of collagen I, inhibiting collagen fibril formation and reducing fibrotic lesions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used, then treatment is provided for fibrotic disorders, but excessive collagen fibril deposition is not prevented or reduced
Solution Approach 1:
The patent introduces engineered antibodies as intermediary molecules that specifically bind to the C-terminal telopeptide of collagen I, preventing direct collagen fibril deposition. These antibodies act as mediators between the immune system and collagen, blocking the harmful interaction without requiring direct removal of collagen, thus resolving the contradiction between providing therapy and preventing excessive deposition.
Solution Approach 2:
The patent modifies the natural collagen structure by targeting a specific region (C-terminal telopeptide) and changing the binding parameters through engineered antibodies with specific affinity and specificity. This parameter change allows selective inhibition of fibril formation while maintaining normal collagen function, thereby improving therapy effectiveness without causing harmful effects.
2Object-generated harmful factors
If collagen fibril formation is inhibited, then fibrotic lesions are reduced, but collagen function may be compromised
Solution Approach 1:
The patent applies local quality by targeting a specific local region of collagen (the C-terminal telopeptide) for antibody binding, rather than affecting collagen globally. This localized approach allows inhibition of fibril formation at the site of fibrosis while preserving the overall structural and functional properties of collagen in non-affected areas, thus reducing fibrotic lesions without compromising collagen function.
Solution Approach 2:
The patent segments the collagen molecule into functional regions, specifically isolating the C-terminal telopeptide as the target for antibody binding. This segmentation allows selective interference with fibril formation through the telopeptide region while leaving the triple-helical structure and other functional domains intact, thereby reducing fibrotic lesions without compromising overall collagen function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies effectively prevent excessive collagen deposition, thereby reducing localized and systemic fibrotic lesions, including those caused by surgical procedures or medical device implantation, and offer a therapeutic approach for conditions like keloids and pulmonary fibrosis.
Implementation Method 1
The engineered antibodies are capable of binding the C-terminal telopeptide of the α2(I) chain of human collagen I
Data Source
AI summary
A chimeric, humanized or single-chain antibody contains a light chain variable region containing the complementarity determining regions of SEQ ID NO: 1, SEQ ID NO:2 and SEQ ID NO:3, and a heavy chain variable region containing the complementarity determining regions SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6. The antibody or antibody fragment thereof is capable of binding the C-terminal telopeptide of the α2(I) chain of human collagen I, and is useful in the treatment of diseases or disorders associated with excessive collagen fibril.